Drug intelligence / Profile preview

Shengruling

Development stage: Unknown
Lead developer: Xi'an Zhouliang Mingkang Biopharmaceutical Technology
Administration: Oral

Overview

Shengruling is a Traditional Chinese Medicine (TCM) capsule developed by Xi'an Zhouliang Mingkang Biopharmaceutical Technology Co., Ltd. for the treatment of breast hyperplasia. It is specifically indicated for patients presenting with the TCM syndrome of liver depression and phlegm coagulation. The drug's efficacy is measured by improvements in breast pain, reduction in the size of breast lumps, and overall improvement in TCM symptoms. It has undergone Phase II clinical testing in China to evaluate its safety and optimal dosage.

Brand names: Shengruling
Other names: Shengruling CapsuleShengruling Jiaonang

Beyond the preview

Go deeper on Shengruling.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shengruling.

Explore the full profile